Basic Stats
| LEI | 549300SI4ZGLG0BLUZ92 |
| CIK | 874015 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ionis Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 2, 2025 |
Exhibit 99.1 Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) – Up to 72% (p<0.0001) placebo-adjusted mean reduction in fasting triglycerides – – 85% (p=0.0002) reduction in acute pancreatitis events, the first and only time achieved for the treatment of sHTG – – Favorable safety and tolerabil |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 2, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commissi |
|
| August 21, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IR |
|
| August 21, 2025 |
Exhibit 99.1 DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema - DAWNZERA demonstrated significant and sustained HAE attack rate reduction and long-term disease control – - Offers longest dosing option for HAE, with dosing every 4 or 8 weeks – - Compelling profile supported by recently published switch data – - Ionis’ seco |
|
| July 30, 2025 |
Exhibit 10.5 Final Execution Version Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. AMENDMENT NO. 4 This Amendment No. 4 (the “Amendment”) to the Collaboration, License and Development Agreement dated December 7th, 2012 (the “Agreement”), is made by and |
|
| July 30, 2025 |
As filed with the Securities and Exchange Commission on July 30, 2025 As filed with the Securities and Exchange Commission on July 30, 2025 Registration No. |
|
| July 30, 2025 |
Exhibit 10.7 Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. AMENDMENT NO. 1 This Amendment No. 1 (the “Amendment”) to the Strategic Collaboration Agreement dated July 31st, 2015 (the “Agreement”), is made by and between (1) ASTRAZENECA AB, a company inco |
|
| July 30, 2025 |
Exhibit 10.3 Execution Copy Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. AMENDMENT NO.2 This Amendment No.2 (“the “Amendment”) to the Collaboration, License and Development Agreement dated December 7th, 2012 (the “Agreement”), is made by and between (1 |
|
| July 30, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| July 30, 2025 |
Strategic Collaboration Agreement Isis Pharmaceuticals, Inc., AstraZeneca AB TABLE OF CONTENTS Exhibit 10.6 Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. Strategic Collaboration Agreement Between Isis Pharmaceuticals, Inc., And AstraZeneca AB TABLE OF CONTENTS ARTICLE 1. RESEARCH COLLABORATION; RIGHT TO OBTAIN EXCLUSIVE LICENSES 2 1.1. Research C |
|
| July 30, 2025 |
Exhibit 10.1 Confidential Execution Copy Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. Collaboration, License and Development Agreement Between Isis Pharmaceuticals, Inc., And AstraZeneca AB COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT This COLLABOR |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| July 30, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ionis Pharmaceuticals, Inc. |
|
| July 30, 2025 |
Exhibit 10.4 Final Execution Version Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. AMENDMENT NO.3 This Amendment No.3 (“the “Amendment”) to the Collaboration, License and Development Agreement dated December 7th, 2012 (the “Agreement”), is made by and b |
|
| July 30, 2025 |
AMENDMENT #1 TO COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT Exhibit 10.2 Execution Copy Certain identified information in this exhibit, marked by [***], has been excluded because it is both (i) not material, and (ii) the type that the registrant treats as private or confidential. AMENDMENT #1 TO COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT This AMENDMENT #1 TO COLLABORATION, LICENSE AND DEVELOPMENT AGREEMENT (this “Amendment”) is entered into as of the |
|
| July 30, 2025 |
Exhibit 99.1 Ionis reports second quarter 2025 financial results and highlights progress on key programs - TRYNGOLZATM delivers $19 million in net product sales in the second quarter 2025 - - Donidalorsen approval in hereditary angioedema (HAE) anticipated next month; Ionis’ second independent launch - - Phase 3 data from the pivotal CORE and CORE2 studies in severe hypertriglyceridemia (sHTG) exp |
|
| June 12, 2025 |
Exhibit 99.1 Ionis announces Dr. Richard Geary, chief development officer to retire; Dr. Holly Kordasiewicz to assume role in January 2026 CARLSBAD, Calif., June 12, 2025 - Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senio |
|
| June 12, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 12, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| June 10, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 5, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| May 19, 2025 |
Exhibit 99.1 Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides – Olezarsen met the primary endpoint with a statistically significant mean reduction in triglycerides versus placebo at 80 mg and 50 mg doses – – Olezarsen met all key secondary endpoints – – Olezarsen demonstrated a favorable safety and tolerability profile – –Nea |
|
| May 19, 2025 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 19, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| April 30, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| April 30, 2025 |
LICENSE AGREEMENT IONIS PHARMACEUTICALS, INC. ONO PHARMACEUTICAL CO., LTD. Dated March 10, 2025 Execution Version Exhibit 10.2 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. LICENSE AGREEMENT BETWEEN IONIS PHARMACEUTICALS, INC. AND ONO PHARMACEUTICAL CO., LTD. Dated March 10, 2025 Execution Version TABLE OF CONTENTS ARTICLE 1 OVERVIEW 1 1.1 Development and Commerc |
|
| April 30, 2025 |
Third Amended Non-Employee Director Compensation Policy As of March 6, 2025 Exhibit 10.1 Third Amended Non-Employee Director Compensation Policy As of March 6, 2025 Ionis Pharmaceuticals, Inc. (“Ionis”) values the contributions made by its Board of Directors. In recognition of these valuable contributions, Ionis will provide each non-employee Director with the compensation described in this policy. Cash Compensation Each non-employee Director will receive cash compensatio |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| April 30, 2025 |
Exhibit 99.1 Ionis reports first quarter 2025 financial results - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - CARLSBAD, Calif., April 30, 2025 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for |
|
| April 25, 2025 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 25, 2025 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 12, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| March 12, 2025 |
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera Exhibit 99.1 Ionis and Ono announce global license agreement for sapablursen in polycythemia vera CARLSBAD, Calif., and Osaka, Japan, March 11, 2025 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of |
|
| February 19, 2025 |
Final Execution Version Exhibit 10.58 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. AMENDMENT NO. 4 This Amendment No. 4 (the “Fourth Amendment”) to the Strategic Collaboration Agreement, dated July 31, 2015, as previously amended by Amendment No. 1 dated October 18, 2 |
|
| February 19, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 19, 2025 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| February 19, 2025 |
Exhibit 99.1 Ionis reports fourth quarter and full year 2024 financial results - First independent launch underway following TRYNGOLZATM approval - - Second independent launch on track with donidalorsen PDUFA August 21, 2025 - - WAINUATM U.S. launch delivering accelerating sequential growth - - Ionis exceeds 2024 financial guidance and provides full year 2025 guidance - CARLSBAD, Calif., February |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| February 19, 2025 |
Exhibit 19 PUBLIC COMPANY OBLIGATIONS Ionis Pharmaceuticals, Inc. (“Ionis”) is a public company, which means it is owned by its stockholders and its securities are publicly traded. Every Ionis employee has an obligation to protect Ionis’ value and assets. When you started employment at Ionis, you signed an Employee Confidential Information and Invention Agreement. In this agreement, you promised t |
|
| December 20, 2024 |
Exhibit 99.1 TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet • TRYNGOLZA shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with FCS; a rare, highly debilitating and life-threatening disease • Indicated for adults with FCS regardless of genetically or |
|
| December 20, 2024 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| November 14, 2024 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d877529dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 14)* Ionis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| November 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Ionis Pharmaceuticals, Inc. |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ionis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| November 6, 2024 |
Exhibit 99.1 Ionis reports third quarter 2024 financial results WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., November 6, 2024 – Ionis Pharmaceuticals, Inc. (N |
|
| November 6, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| September 12, 2024 |
Underwriting Agreement, dated September 9, 2024. Exhibit 1.1 Ionis Pharmaceuticals, Inc. 11,500,000 shares of common stock, par value $0.001 per share Underwriting Agreement September 9, 2024 Morgan Stanley & Co. LLC Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Schedule I hereto, c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10 |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Comm |
|
| September 10, 2024 |
11,500,000 Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275741 PROSPECTUS SUPPLEMENT (To Prospectus dated November 24, 2023) 11,500,000 Shares Common Stock Ionis Pharmaceuticals, Inc. is offering 11,500,000 shares of its common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “IONS.” The last reported sale price of our common stock on the Nasdaq Global Select Mar |
|
| September 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 Ionis Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carr |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Comm |
|
| September 9, 2024 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 9, 2024 Filed Pursuant to Rule 424(b)(5) Registration No. 333-275741 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities a |
|
| August 5, 2024 |
As filed with the Securities and Exchange Commission on August 5, 2024 As filed with the Securities and Exchange Commission on August 5, 2024 Registration No. |
|
| August 5, 2024 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 IONIS PHARMACEUTICALS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $. |
|
| August 1, 2024 |
Exhibit 99.1 Ionis reports second quarter 2024 financial results WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., August 1, 2024 – Ionis Pharmaceuticals, Inc |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| August 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| August 1, 2024 |
Exhibit 10.1 SECOND AMENDMENT TO AMENDED AND RESTATED LEASE This SECOND AMENDMENT TO AMENDED AND RESTATED LEASE (“Amendment”) is made as of June 11, 2024 (the “Effective Date”), by and between LOTS 21 & 22 OWNER (DE) LLC, a Delaware limited liability company (“Landlord”), and IONIS PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). R E C I T A L S: A. Landlord and Tenant are parties to that |
|
| August 1, 2024 |
CONFIDENTIAL Execution Version Exhibit 10.2 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. Amended and Restated License Agreement By and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. Dated June 18, 2024 CONFIDENTIAL TABLE OF CONTENTS ARTICLE 1 |
|
| June 18, 2024 |
Exhibit 99.1 Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema • Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe • Ionis plans to independently bring donidalorsen to U.S. patients, if approved CARLSBAD, Calif., June 18, 2024 - Ionis Pharmaceuticals |
|
| June 18, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 18, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| June 10, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| May 31, 2024 |
Exhibit 99.1 Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema • Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over tim |
|
| May 31, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS Em |
|
| May 7, 2024 |
Exhibit 99.1 Ionis reports first quarter 2024 financial results WAINUATM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE; preparing regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., May 7, 2024 – Ionis Pharmaceuticals, Inc. (N |
|
| May 7, 2024 |
EXHIBIT 10.1 IONIS PHARMACEUTICALS, INC. ADVISORY SERVICES AGREEMENT (“SUMMARY PAGE”) Date of Advisory Services Agreement: (“Agreement”) March 15, 2024 (“Effective Date”). Name of Advisor: Onaiza Cadoret-Manier (hereinafter “Advisor”). Scope of Advisory Services: As mutually agreed by Advisor and Ionis’ CEO by separate scopes of work. Duration of Advisory Services (the “Advisory Period”): An initi |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| April 25, 2024 |
TABLE OF CONTENTS SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 25, 2024 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 8, 2024 |
Exhibit 99.1 Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome – Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – Results demonstrate olezarsen may represent a novel treatment option for this rare, l |
|
| April 8, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 7, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| February 29, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| February 21, 2024 |
Exhibit 10.3 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into this [DAY] day of [MONTH], [YEAR] by and between Ionis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [DIRECTOR/OFFICER NAME] (“Agent”). RECITALS WHEREAS, Agent performs a valuable service to the Company in [his/her] capacity as [TITLE]; WHEREAS, the stockholders of the Company |
|
| February 21, 2024 |
Exhibit 10.80 Execution Version Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. License Agreement By and Between Ionis Pharmaceuticals, Inc. and Otsuka Pharmaceutical Co., Ltd. Dated December 15, 2023 TABLE OF CONTENTS ARTICLE 1 OVERVIEW 1 1.1 Development and Commerciali |
|
| February 21, 2024 |
List of Subsidiaries for the Registrant Exhibit 21.1 LIST OF SUBSIDIARIES FOR THE REGISTRANT Akcea Therapeutics, Inc., a Delaware Corporation Akcea Therapeutics Canada Inc., a Canadian Corporation Akcea Therapeutics Germany GmbH, a German Corporation Akcea Therapeutics UK Limited, a United Kingdom Limited Private Company Akcea Therapeutics Ireland Limited, an Irish Private Company Akcea Therapeutics Italia S.r.l., an Italian Company Akc |
|
| February 21, 2024 |
Exhibit 10.25 FIRST AMENDMENT TO AMENDED AND RESTATED LEASE THIS FIRST AMENDMENT TO AMENDED AND RESTATED LEASE (this “Amendment”) is entered into as of November 6, 2023, by and between LOTS 21 & 22 OWNER (DE) LLC, a Delaware limited liability company (“Landlord”), and IONIS PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). R E C I T A L S: A. Landlord and Tenant are parties to that certain |
|
| February 21, 2024 |
Registrant’s Amended and Restated Clawback Policy Exhibit 97 Ionis Pharmaceuticals, Inc. Amended and Restated Clawback Policy 1. Introduction The Board of Directors (the “Board”) of Ionis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Amended and Restated Clawback Policy (this “Policy”) providing for the Company’s recoupment of Recove |
|
| February 21, 2024 |
Exhibit 99.1 Ionis reports fourth quarter and full year 2023 financial results WAINUATM approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthrough Therapy designation by the FDA for FCS Ionis provides full year 2024 financial gu |
|
| February 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 21, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| February 13, 2024 |
IONS / Ionis Pharmaceuticals, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d749650dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 13, 2024 |
IONS / Ionis Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Ionis Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 462222100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 22, 2024 |
Exhibit 99.1 Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema ● Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks ● Donidalorsen demonstrated a favorable safety and tolerability prof |
|
| January 22, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 22, 2024 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| December 22, 2023 |
Exhibit 99.1 WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis • U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life • Addition |
|
| December 22, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| December 18, 2023 |
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema Exhibit 99.1 Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema – Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patients – Ionis plans to independently bring donidalorsen to U.S. patients if approved – Donidalorsen Phase 3 results expected in the first half of 2024 CARLSBAD, Calif., Dec. 18, 202 |
|
| December 18, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 18, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| December 14, 2023 |
Ionis announces the appointment of Michael Yang to Board of Directors Exhibit 99.1 Ionis announces the appointment of Michael Yang to Board of Directors CARLSBAD, Calif., Dec. 14, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang’s appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of b |
|
| December 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| November 24, 2023 |
As filed with the Securities and Exchange Commission on November 24, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 24, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 24, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-3 (Form Type) Ionis Pharmaceuticals, Inc. |
|
| November 2, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 2, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| November 2, 2023 |
EXECUTION VERSION Exhibit 10.1 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. Collaboration and License Agreement between Ionis Pharmaceuticals, Inc. and Novartis Pharma AG COLLABORATION AND LICENSE AGREEMENT This COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is |
|
| November 2, 2023 |
Confidential Execution Version Exhibit 10.3 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. Research, Development, and License Agreement Among Ionis Pharmaceuticals, Inc., And F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc. Confidential Execution Version RESEARCH, DE |
|
| November 2, 2023 |
Exhibit 99.1 Ionis reports third quarter 2023 financial results Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients with FCS; on track for regulatory filings in early 2024 Eplontersen marketing applications accepted for review in the EU and Canada; potential U.S. approval in December |
|
| November 2, 2023 |
Exhibit 10.2 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. AMENDED AND RESTATED LEASE AGREEMENT DATED AS OF AUGUST 21, 2023 Between LOTS 21 & 22 OWNER (DE) LLC a Delaware limited liability company AS LANDLORD and IONIS PHARMACEUTICALS, INC., a Delaware corporation AS T |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| September 27, 2023 |
Exhibit 99.1 Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease ● Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by Ionis ● Ionis to receive a $60 million upfront payment CARLSBAD, Calif., Sept. 27, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today an |
|
| September 27, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 27, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) |
|
| September 26, 2023 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 26, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) |
|
| September 26, 2023 |
Exhibit 99.1 Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome • Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo • First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent • |
|
| August 23, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IR |
|
| August 22, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IR |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No. |
|
| August 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Ionis Pharmaceuticals, Inc. |
|
| August 9, 2023 |
2850 Gazelle Ct Carlsbad, CA 92010 Exhibit 10.3 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. CONFIDENTIAL June 29, 2023 AstraZeneca AB SE-431 83 Mölndal Gothenburg, Sweden Attention: Kajsa Lundqvist Re: Collaboration and License Agreement dated December 6, 2021, by an |
|
| August 9, 2023 |
EXHIBIT 10.2 FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT THIS FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT (this “Amendment”) is entered into as of June 15, 2023, by and between IONIS PHARMACEUTICALS, INC., a Delaware corporation (“Seller”) and OXFORD I ASSET MANAGEMENT USA INC., a Delaware corporation (“Buyer”). RECITALS: A. Seller and Buyer are parties to that certain Purchase and Sale Agre |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| August 9, 2023 |
Exhibit 10.1 Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. AMENDMENT NO. 3 TO COLLABORATION AND LICENSE AGREEMENT This Amendment No. 3 to Collaboration and License Agreement (“Third Amendment”) is made and entered into effective as of 27th April 2023 (“Third Amendment |
|
| August 9, 2023 |
Exhibit 99.1 Ionis reports second quarter 2023 financial results Reported Phase 3 data showing eplontersen continued to show improvement in ATTRv-PN through 85 weeks; December 22, 2023 PDUFA date Completed enrollment in donidalorsen OASIS-HAE study and eplontersen CARDIO-TTRansform ATTR-CM study keeping Phase 3 data readouts on track On track to achieve 2023 financial guidance CARLSBAD, Calif., Au |
|
| August 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| August 4, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| August 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 2, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| August 3, 2023 |
Exhibit 99.1 Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease • Builds on existing collaboration with Novartis for pelacarsen, which is currently being evaluated in a Phase 3 cardiovascular outcome study with data expected in 2025 • Ionis’ new and advanced technologies will be used to create next generation compound targeting Lp(a) • Ionis wi |
|
| July 10, 2023 |
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks Exhibit 99.1 Eplontersen continued to show improvement in ATTRv-PN through 85 weeks • Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeks • Data further strengthen eplontersen's differentiated profile, positioning it to be an important potential treatment for patients with ATTRv-PN CARLSBAD, Calif., |
|
| July 10, 2023 |
Exhibit 99.2 Eplontersen: NEURO-TTRansform Week 85 Topline Results July 10, 2023 Nasdaq: IONS Forward-Looking Statements This presentation includes forward-looking statements regarding our business and the therapeutic and commercial potential of eplontersen, and Ionis' technologies. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forw |
|
| July 10, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| June 12, 2023 |
Ionis prices private placement of convertible senior notes EX-99.1 Exhibit 99.1 Ionis prices private placement of convertible senior notes June 8, 2023 at 1:09 AM EDT CARLSBAD, Calif., June 7, 2023 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the “notes”) in a private placement (the “offering”) to qualified institutional buyers |
|
| June 12, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| June 12, 2023 |
EX-4.1 Exhibit 4.1 IONIS PHARMACEUTICALS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of June 12, 2023 1.75% Convertible Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 14 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. Designation |
|
| June 9, 2023 |
IONS / Ionis Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Ionis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 462222100 Date of Event Which Requires Filing of this Statement: May 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| June 6, 2023 |
Ionis announces proposed private placement of convertible notes EX-99.1 Exhibit 99.1 Ionis announces proposed private placement of convertible notes CARLSBAD, Calif., June 6, 2023 – Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement (the “offering”) to qualified ins |
|
| June 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| June 6, 2023 |
EX-99.2 Exhibit 99.2 In the confidential preliminary offering memorandum to be used in connection with a private placement to qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended, by Ionis Pharmaceuticals, Inc., the Company provided the following overview of the Company’s business as updates or supplements to the information provided in the Company’s previ |
|
| June 5, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 1, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| May 3, 2023 |
Exhibit 10.4 Execution Version Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential HTT Research, Development, Option and License Agreement Among Isis Pharmaceuticals, Inc., And F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc. HTT RESEARCH, DEVELOPMENT, OPTION AND LICENSE A |
|
| May 3, 2023 |
Exhibit 10.3 Ionis Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (Amended & Restated 2002 Non-Employee Directors’ Stock Option Plan) Ionis Pharmaceuticals, Inc. (the “Company”), pursuant to its Amended & Restated 2002 Non-Employee Directors’ Stock Option Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of stock units set forth below (the “Awar |
|
| May 3, 2023 |
Second Amended Non-Employee Director Compensation Policy Exhibit 10.1 Second Amended Non-Employee Director Compensation Policy As of April 24, 2023 Ionis Pharmaceuticals, Inc. (“Ionis”) values the contributions made by its Board of Directors. In recognition of these valuable contributions, Ionis will provide each non-employee Director with the compensation described in this policy. Cash Compensation Each non-employee Director will receive cash compensat |
|
| May 3, 2023 |
Exhibit 99.1 Ionis reports first quarter 2023 financial results QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive Phase 3 eplontersen ATTRv-PN data; December 22, 2023 PDUFA date On track to achieve 2023 financial guidance CARLSBAD, Calif., May 3, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”), today reported financial results for the first quarter of 2023. |
|
| May 3, 2023 |
Registrant's Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan, Exhibit 10.2 IONIS PHARMACEUTICALS, INC. Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan Adopted by the Board of Directors September 11, 2001 Approved by Stockholders May 31, 2002 Effective Date: May 31, 2002 Amended: April 20, 2006 (Amendment approved by Board on December 12, 2005 and April 20, 2006 and by the Stockholders on May 3, 2006) Amended: June 5, 2008 (Amendment appro |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| May 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 3, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS Em |
|
| April 26, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| April 26, 2023 |
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS EX-99.1 2 brhc20051944ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS • Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) • Approval based on reduction of neurofilament, a biomarker associated with neuronal damage in ALS • QALSODY joins S |
|
| April 24, 2023 |
Exhibit 99.1 Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks • NEURO-TTRansform study met all co-primary and secondary endpoints • Positive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal d |
|
| April 24, 2023 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| April 20, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 20, 2023 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 27, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 27, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| March 27, 2023 |
Exhibit 99.1 Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN − Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks − 35 and 66-week data to be presented at the American Academy of Neurology (AAN) Annual Meeting in April CARLSBAD, Calif., March 27, 2023 – |
|
| February 22, 2023 |
Exhibit 99.1 Ionis reports fourth quarter and full year 2022 financial results Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expanding with two new Phase 3 programs Ionis provides full year 2023 financial guidance CARLSBAD, Calif., February 22, 2023 – Ionis Phar |
|
| February 22, 2023 |
Exhibit 10.10 Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan Grant Notice Optionee: «Name» Date of Grant: «Date» Ionis Pharmaceuticals, Inc. Non-Statutory Stock Option Agreement Ionis Pharmaceuticals, Inc. (the “Company”), pursuant to its Amended and Restated 2002 Non-Employee Directors’ Stock Option Plan (the “Plan”), hereby grants to Optionholder an option to purchase the nu |
|
| February 22, 2023 |
Exhibit 10.26 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE AGREEMENT DATED OCTOBER 20, 2022 Between 2850 2855 & 2859 GAZELLE OWNER (DE) LLC a Delaware limited liability com |
|
| February 22, 2023 |
Exhibit 10.29 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DEFEASANCE ACCOUNT AGREEMENT THIS DEFEASANCE ACCOUNT AGREEMENT (this “Agreement”) is entered into as of October 20, 2022 by |
|
| February 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 22, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| February 22, 2023 |
Exhibit 10.14 Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan Restricted Stock Unit Agreement Pursuant to the Restricted Stock Unit Grant Notice (“Grant Notice”) and this Restricted Stock Unit Agreement and in consideration of your services, Ionis Pharmaceuticals, Inc. (the “Company”) has awarded you a Restricted Stock Unit Award (the “Award”) under its 2011 Equity Incentive Plan (the “Plan |
|
| February 22, 2023 |
LIST OF SUBSIDIARIES FOR THE REGISTRANT Exhibit 21.1 LIST OF SUBSIDIARIES FOR THE REGISTRANT Akcea Therapeutics, Inc., a Delaware Corporation Akcea Therapeutics Canada Inc., a Canadian Corporation Akcea Therapeutics France SAS, a French Company* Akcea Therapeutics Germany GmbH, a German Corporation Akcea Therapeutics UK Limited, a United Kingdom Limited Private Company Akcea Securities Corporation, a Massachusetts Corporation* Akcea The |
|
| February 22, 2023 |
Exhibit 10.80 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION AND LICENSE AGREEMENT BETWEEN Metagenomi, Inc. AND Ionis Pharmaceuticals, Inc. Dated November 10, 2022 TA |
|
| February 22, 2023 |
Annual Report on Form 10-K for the quarter and year ended December 31, 2022 Exhibit 10.23 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LEASE AGREEMENT by and between SUDBERRY DEVELOPMENT, INC., a California corporation, as Landlord and IONIS PHARMACEUTIC |
|
| February 22, 2023 |
Exhibit 10.28 DEFEASANCE ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT THIS DEFEASANCE ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT (this “Agreement”) dated as of October 20, 2022 is made by and among IONIS GAZELLE, LLC, a Delaware limited liability company (“Original Borrower”), DHC UBSCM 17 C3 SUCCESSOR BORROWER-R, LLC, a Delaware limited liability company (“Successor Borrower”), WELLS FARGO BANK |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| February 22, 2023 |
Exhibit 14 MESSAGE FROM THE CEO At Ionis, we dream big and are committed to bringing life-changing medicines to patients with unmet medical needs. |
|
| February 22, 2023 |
Exhibit 10.27 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DEFEASANCE PLEDGE AND SECURITY AGREEMENT THIS DEFEASANCE PLEDGE AND SECURITY AGREEMENT (this “Agreement”) dated as of O |
|
| February 22, 2023 |
Exhibit 10.25 Execution Copy CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT Between IONIS PHARMACEUTICALS, INC. “Seller” and OXFORD I ASSET MANAGEMENT U |
|
| February 22, 2023 |
Exhibit 10.24 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PURCHASE AND SALE AGREEMENT Between IONIS GAZELLE, LLC “Seller” and 2850 2855 & 2859 GAZELLE OWNER (DE) LLC “Buyer” wit |
|
| February 22, 2023 |
Form of Option Agreement under the 2011 Equity Incentive Plan Exhibit 10.13 Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan Option Agreement (Nonstatutory Stock Option) For Options Granted After January 1, 2022 Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Ionis Pharmaceuticals, Inc. (the “Company”) has granted you an option under its 2011 Equity Incentive Plan (the “Plan”) to purchase the number of shares of t |
|
| February 22, 2023 |
Exhibit 10.16 Ionis Pharmaceuticals, Inc. Performance Based Restricted Stock Unit Grant Notice (2011 Equity Incentive Plan) Ionis Pharmaceuticals, Inc. (the “Company”), pursuant to its Amended and Restated 2011 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Performance Based Restricted Stock Unit (“PRSU”) Award for the number of stock units set forth below (the “Award”). The Aw |
|
| February 22, 2023 |
Exhibit 10.81 Execution Version Certain portions of this exhibit, marked by [***], have been excluded because they are both not material and are the type that the registrant treats as private or confidential. Royalty Purchase Agreement By and Between Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. (for the limited purposes set forth herein) and Royalty Pharma Investments 2019 ICAV Dated a |
|
| February 14, 2023 |
EX-99.B 2 d394406dex99b.htm EX-99.B Exhibit B POWER OF ATTORNEY The Undersigned, Hugo van Neutegem herewith gives Power of Attorney to Mrs. Nathalie M.A. Isidora-Kwidama, born in Curacao on, holder of a passport issued by the Kingdom of the Netherlands, with number, to represent the Company in the broadest sense of the word and in the best interest of the Company and further to do if were the Unde |
|
| February 14, 2023 |
IONS / Ionis Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A 1 d394406dsc13ga.htm SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing This Statement) Check the appropriate box to |
|
| February 9, 2023 |
IONS / Ionis Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Ionis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 462222100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 9, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 8, 2023 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IR |
|
| November 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-19125 33-0336973 (State or Other Jurisdiction of Incorporation) (Commission File No.) ( |
|
| November 9, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| November 9, 2022 |
Exhibit 99.1 Ionis reports third quarter financial results Advanced key priorities: initiated manufacturing infrastructure project to support growth Increased 2022 cash and investments guidance CARLSBAD, Calif., November 9, 2022 ? Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the ?Company?) today reported financial results for the third quarter of 2022. Financial results are summarized below: Three |
|
| November 9, 2022 |
Exhibit 10.1 CONFIDENTIAL Execution Version Portions of this exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 2 TO COLLABORATION AND LICENSE AGREEMENT THIS AMENDMENT NO. 2 TO COLLABORATION AND LICENSE AGREEMENT (?Second Amendment?) is made and entered into effective as of July 28, 2022 (?Second Amendment E |
|
| November 4, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 31, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| November 4, 2022 |
Ionis announces positive results from fesomersen development program Exhibit 99.1 Ionis announces positive results from fesomersen development program − Positive Phase 2b data from RE-THINC ESRD study of fesomersen in patients on hemodialysis presented at Kidney Week 2022 − Ionis to regain rights to fesomersen from Bayer CARLSBAD, Calif., November 4, 2022 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the Phase 2b RE-THINC ESRD s |
|
| October 24, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 20, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| October 12, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 6, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IR |
|
| August 9, 2022 |
Exhibit 10.1 Confidential CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. FIRST AMENDMENT TO FACTOR B DEVOLOPMENT, COLLABORATION, OPTION AND LICENSE AGREEMENT This FIRST AMENDMENT TO FACTOR B DEVELOPMENT, COLLABORATION, OPTION |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| August 9, 2022 |
Exhibit 99.1 Ionis reports second quarter financial results and recent business achievements Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22 Tofersen NDA under priority review, PDUFA January 25, 2023 Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen BALANCE Phase 3 studies On track to achieve 2022 financial guidance Webcast today, August 9, 2022, at 11:30 a. |
|
| July 28, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 22, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| July 19, 2022 |
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE Exhibit 99.1 IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE LEO SHUMACHER, derivatively on behalf ) of IONIS PHARMACEUTICALS, INC., ) ) Plaintiff, ) ) v. ) JOSEPH LOSCALZO, M.D., PH.D., ) BRETT P. MONIA, PH.D., SPENCER R. ) BERTHELSEN, M.D., ALLENE M. DIAZ, ) MICHAEL HAYDEN, PH.D., JOANE. ) C.A. No. 2022-0059-LWW HERMAN, JOSEPH KLEIN, III, ) FREDERICK T. MUTO, B. LYNNE ) PARSHALL and JOSEPH H. |
|
| July 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(D) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 18, 2022 IONIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 000-19125 33-0336973 (Commission F |
|
| July 18, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| July 11, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 11, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| July 11, 2022 |
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study Exhibit 99.1 Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study - Positive data from a Phase 2 study of IONIS-FB-LRx support further development for treatment of patients with IgA nephropathy CARLSBAD, Calif., July 11, 2022 ? Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that its long-standing partner, Roche, will license and advance ION |
|
| June 21, 2022 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 21, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| June 21, 2022 |
Exhibit 99.1 Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) ? Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN ? Eplontersen demonstrated a favorable safety profile ? Ionis and AstraZene |
|
| June 6, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| May 4, 2022 |
Exhibit 99.1 Ionis reports first quarter financial results and recent business achievements On track to achieve 2022 financial guidance Webcast today, May 4, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 4, 2022 ? Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements. ?We are off to a strong start this ye |
|
| May 4, 2022 |
Registrant’s Amended and Restated Severance Benefit Plan dated March 17, 2022 Exhibit 10.1 Amended and Restated Ionis Pharmaceuticals, Inc. Severance Benefit Plan 1. Introduction. This Amended and Restated Ionis Pharmaceuticals, Inc. Severance Benefit Plan (the ?Plan?) is adopted by Ionis Pharmaceuticals, Inc. (the ?Company?) on March 17, 2022 (the ?Effective Date?) and amends and restates the Severance Benefit Plan established by the Company on October 18, 2018. The Plan p |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 4, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS Em |
|
| April 20, 2022 |
DEF 14A 1 ny20002718x1def14a.htm DEF 14A SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definiti |
|
| April 20, 2022 |
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 21, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 17, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| February 25, 2022 |
Exhibit 10.83 CONFIDENTIAL Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT This Amendment No. 1 to Collaboration and License Agreement (?First Amendment?) |
|
| February 25, 2022 |
Exhibit 10.60 IONIS PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT (?SUMMARY PAGE?) This Fourth Amended and Restated Strategic Advisory Services Agreement is entered into by and between Lyme Pinnacle Consulting Inc., for the services of B. Lynne Parshall, and is made effective as of February 22, 2022, and amends and restates the Strategic Advisory Service A |
|
| February 25, 2022 |
LIST OF SUBSIDIARIES FOR THE REGISTRANT Exhibit 21.1 LIST OF SUBSIDIARIES FOR THE REGISTRANT Akcea Therapeutics, Inc., a Delaware Corporation Akcea Therapeutics Canada Inc., a Canadian Corporation Akcea Therapeutics France SAS, a French Company Akcea Therapeutics Germany GmbH, a German Corporation Akcea Therapeutics UK Limited, a United Kingdom Limited Private Company Akcea Securities Corporation., a Massachusetts Corporation Akcea Ther |
|
| February 25, 2022 |
Description of the Registrant’s Securities Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Ionis Pharmaceuticals, Inc. (the ?Company?) had one class of securities, its Common Stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). Description of Common Stock General The following desc |
|
| February 25, 2022 |
Exhibit 10.84 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]? COLLABORATION AND LICENSE AGREEMENT by and between Akcea Therapeutics, Inc. and AstraZeneca AB TABLE OF CONTENTS Page ARTICLE 1 OVERVIEW 1 1.1 Development and Commerc |
|
| February 25, 2022 |
Exhibit 10.19 Ionis Pharmaceuticals, Inc. Performance Based Restricted Stock Unit Grant Notice (2011 Equity Incentive Plan) Ionis Pharmaceuticals, Inc. (the ?Company?), pursuant to its Amended and Restated 2011 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Performance Based Restricted Stock Unit (?PRSU?) Award for the number of stock units set forth below (the ?Award?). The Aw |
|
| February 24, 2022 |
Exhibit 99.1 Ionis reports fourth quarter and full year 2021 financial results and recent business achievements Exceeded 2021 financial guidance with revenues of more than $800 million Webcast today, February 24, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., February 24, 2022 ? Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year end |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| February 11, 2022 |
IONS / Ionis Pharmaceuticals Inc / BB BIOTECH AG - SC 13G/A Passive Investment United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* IONIS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| February 10, 2022 |
IONS / Ionis Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01194-ionispharmaceuticals.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Ionis Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 462222100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box |
|
| February 9, 2022 |
IONS / Ionis Pharmaceuticals Inc / ARK Investment Management LLC - SC 13G Passive Investment SC 13G 1 tm225659d6sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Ionis Pharmaceuticals, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 462222100 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 31, 2022 |
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program Exhibit 99.1 Pfizer and Ionis announce discontinuation of vupanorsen clinical development program NEW YORK and CARLSBAD, Calif., Jan. 31, 2022 ? Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for poten |
|
| January 31, 2022 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 24, 2022 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| December 7, 2021 |
Ionis and AstraZeneca to develop and commercialize eplontersen Exhibit 99.1 Ionis and AstraZeneca to develop and commercialize eplontersen ? Collaboration expected to enable faster and deeper market penetration into growing global TTR amyloidosis market ? The companies will jointly develop and commercialize eplontersen in the U.S., AstraZeneca has exclusive rights to commercialize in rest of the world ? Bolsters Ionis? commercial organization as it prepares f |
|
| December 7, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 6, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| November 26, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 26, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| November 24, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 24, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) ( |
|
| November 24, 2021 |
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen Exhibit 99.1 Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen ? Study met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested ? Key secondary endpoints were met including statistically significant reductions in triglycerides and angiopoietin- |
|
| November 3, 2021 |
Exhibit 10.1 CONFIDENTIAL EXECUTION VERSION CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. Amended and Restated Neurology Drug Discovery and Development Collaboration, Option and License Agreement Between Ionis Pharmaceuticals |
|
| November 3, 2021 |
Exhibit 10.2 Confidential Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. COLLABORATION AND LICENSE AGREEMENT between BICYCLETX LIMITED and IONIS PHARMACEUTICALS, INC. Dated as of July 9, 2021 Confidential TAB |
|
| November 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 3, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| November 3, 2021 |
Exhibit 99.1 Ionis reports third quarter 2021 financial results and recent business achievements Olezarsen (IONIS-APOCIII-LRx) Phase 3 CORE study in patients with sHTG initiated Donidalorsen (IONIS-PKK-LRx) Phase 2 data to be presented at ACAAI Annual Meeting; Phase 3 initiation on track for year-end Tofersen Phase 3 VALOR study missed primary endpoint; signs of reduced disease progression observe |
|
| October 18, 2021 |
Ionis’ partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS Exhibit 99.1 Ionis? partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS ? In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced disease progression across multiple secondary and exploratory endpoints were observed ? The tota |
|
| October 18, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (I |
|
| August 5, 2021 |
As filed with the Securities and Exchange Commission on August 5, 2021 Registration No. 333- S-8 1 brhc10027646s8.htm S-8 As filed with the Securities and Exchange Commission on August 5, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IONIS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0336973 (State of Incorporation) (I.R.S. Emplo |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| August 4, 2021 |
EX-99.1 2 brhc10027562ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis reports second quarter 2021 financial results and recent business achievements Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics’ technology potentially expands LICA technology capabilities Webcast today, August 4, 2021, at 11:30 a.m. Eastern Time CARLSBAD, |
|
| August 4, 2021 |
Amended Board Compensation Policy Exhibit 10.1 Non-Employee Director Compensation Policy Amended June 2, 2021 Ionis Pharmaceuticals, Inc. (?Ionis?) values the contributions made by its Board of Directors. In recognition of these valuable contributions, Ionis will provide each non-employee Director with the compensation described in this policy. Cash Compensation Each non-employee Director will receive cash compensation based on hi |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| June 4, 2021 |
Ionis announces changes to its board of directors at annual meeting of stockholders Exhibit 99.1 Ionis announces changes to its board of directors at annual meeting of stockholders - Joseph Loscalzo, M.D., Ph.D., appointed chairman of the board - Ionis founder and Executive Chairman Stanley T. Crooke, M.D., Ph.D., retires from the board - Breaux B. Castleman retires from the board - Allene M. Diaz appointed to the board CARLSBAD, Calif., June 2, 2021 ? Ionis Pharmaceuticals, Inc. |
|
| June 4, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS E |
|
| May 20, 2021 |
DEFA14A 1 brhc10024953defa14a.htm DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 5, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS Em |
|
| May 5, 2021 |
Exhibit 99.1 Ionis reports first quarter 2021 financial results and recent business achievements On track to achieve 2021 guidance Webcast today, May 5, 2021, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 5, 2021 ? Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2021 and recent business highlights. ?In the first quarter, we took important |
|
| May 5, 2021 |
Quarterly Report - IONIS PHARMACEUTICALS INC 10-Q 3-31-2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
|
| May 5, 2021 |
Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXLUDED INFORMATION HAS BEEN MARKED WITH "[***]". October 21, 2020 Pfizer Inc. 235 East 42nd Street New York, NY 10017 Attention: James Rusnak, M.D., Ph.D. Re: AKCEA-ANGPTL3-LRx License Agreement Dear Dr. Rusnak: Thi |
|
| May 5, 2021 |
Non-Employee Director Compensation Policy EX-10.2 3 ex102.htm EXHIBIT 10.2 Exhibit 10.2 Adopted by the Board of Directors March 26, 2021 Non-Employee Director Compensation Policy Ionis Pharmaceuticals, Inc. (“Ionis”) values the contributions made by its Board of Directors. In recognition of these valuable contributions, Ionis will provide each non-employee Director with the compensation described in this policy. Cash Compensation Each non |
|
| April 23, 2021 |
Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? D |
|
| April 23, 2021 |
DEFA14A 1 nc10023262x2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 13, 2021 |
Ionis prices private placement of convertible senior notes EXHIBIT 99.2 Ionis prices private placement of convertible senior notes April 8, 2021 at 7:05 AM EDT CARLSBAD, Calif., April 8, 2021 /PRNewswire/ ? Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $550.0 million aggregate principal amount of 0% Convertible Senior Notes due 2026 (the ?notes?) in a private placement (the ?offering?) to qualified institutional buyers pursuant |
|
| April 13, 2021 |
Form of Warrant Confirmation for Convertible Senior Notes due 2026 EXHIBIT 10.2 THE SECURITIES REPRESENTED HEREBY (THE ?WARRANTS?) WERE ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND THE WARRANTS MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQ |
|
| April 13, 2021 |
Ionis announces proposed private placement of convertible notes EX-99.1 EXHIBIT 99.1 Ionis announces proposed private placement of convertible notes April 6, 2021 at 4:36 PM EDT CARLSBAD, Calif., April 6, 2021 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the “notes”) in a private |
|
| April 13, 2021 |
Table of Contents Exhibit 4.1 IONIS PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of April 12, 2021 0% Convertible Senior Notes due 2026 Table of Contents TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 13 ARTICLE 2 ISSUE, DESCRIPTION, EXECUTION, REGISTRATION AND EXCHANGE OF NOTES Section 2.01. |
|
| April 13, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| April 13, 2021 |
Form of Convertible Note Hedge Confirmation for Convertible Senior Notes due 2026 EX-10.1 3 d158901dex101.htm EX-10.1 EXHIBIT 10.1 [Dealer Name] [Dealer Address] [], 2021 To: Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 Attention: General Counsel Email: [email protected] Re: [Base][Additional] Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entere |
|
| April 6, 2021 |
Costs Associated with Exit or Disposal Activities SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| March 29, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF IONIS PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) As adopted March 26, 2021 TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 2 Section 6. Special Meeti |
|
| March 29, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| March 29, 2021 |
Ionis Pharmaceuticals, Inc. Code of Ethics and Business Conduct EX-14.1 3 brhc10022399ex14-1.htm EXHIBIT 14.1 Exhibit 14.1 Ionis Pharmaceuticals, Inc. Code of Ethics and Business Conduct Message from the CEO At Ionis, we dream big and are committed to bringing life-changing medicines to patients with unmet medical needs. With that goal comes a responsibility to behave ethically and conduct ourselves with integrity. Doing the right thing is not always easy. But |
|
| March 23, 2021 |
Ionis’ partner provides update on clinical studies evaluating tominersen (IONIS-HTTRx) Exhibit 99.1 Ionis? partner provides update on clinical studies evaluating tominersen (IONIS-HTTRx) - Dosing to stop in Phase III clinical study of tominersen and paused in the open-label extension study (GEN-EXTEND) - The Phase I PK/PD study (GEN-PEAK) of tominersen and the observational Roche HD Natural History Study will continue - No new or emerging safety signals for tominersen were identifie |
|
| March 23, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 22, 2021 IONIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation) 000-19125 33-0336973 (Commission File No.) (IRS |
|
| February 24, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| February 24, 2021 |
LIST OF SUBSIDIARIES FOR THE REGISTRANT Exhibit 21.1 LIST OF SUBSIDIARIES FOR THE REGISTRANT Akcea Therapeutics, Inc., a Delaware Corporation Akcea Therapeutics Canada Inc., a Canadian Corporation Akcea Therapeutics France SAS, a French Company Akcea Therapeutics Germany GmbH, a German Corporation Akcea Therapeutics UK Limited, a United Kingdom Limited Private Company Akcea Securities Corporation., a Massachusetts Corporation Akcea Ther |
|
| February 24, 2021 |
Execution Copy EXHIBIT 10.80 IONIS PHARMACEUTICALS, INC. ADVISORY SERVICES AGREEMENT (?SUMMARY PAGE?) Date of Advisory Services Agreement: (?Agreement?) December 17, 2020 (?Effective Date?). Name of Advisor: Stanley T. Crooke (hereinafter ?Advisor?). Scope of Advisory Services: As set forth on Schedule A attached hereto. Duration of Advisory Services (the ?Advisory Period?): An initial term beginn |
|
| February 24, 2021 |
Exhibit 10.46 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. Research Collaboration, Option and License Agreement Between Isis Pharmaceuticals, Inc. And Janssen Biotech Inc. Confidential RESEARCH COLLABORATION, OPTION AND LICE |
|
| February 24, 2021 |
EXHIBIT 10.81 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH ?[***]?. December 31, 2020 Biogen MA Inc. 225 Binney Street Cambridge, MA 02142 Attention: Chief Legal Officer Email: [***]@biogen.com Re: [***] Collaboration Program Dear An |
|
| February 24, 2021 |
EXHIBIT 10.61 IONIS PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED STRATEGIC ADVISORY SERVICES AGREEMENT (?SUMMARY PAGE?) This Third Amended and Restated Strategic Advisory Services Agreement is entered into by and between Lyme Pinnacle Consulting Inc., for the services of B. Lynne Parshall, and is made effective as of February 22, 2021, and amends and restates the Strategic Advisory Service Agr |
|
| February 24, 2021 |
Annual Report - IONIS PHARMACEUTICALS, INC. 10-K 12-31-2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. |
